Shell PLC vs BIO-TECHNE Corp — how do they compare? Shell PLC trades at $90.53 (market cap $245.77B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Shell PLC is far larger — about 21.9× BIO-TECHNE Corp's market cap, and Shell PLC pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| SHEL | TECH | |
|---|---|---|
Market Cap | $245.77B | $11.24B |
Sector | Energy | Health |
52-Week High | $94.15 | $72.29 |
52-Week Low | $70.31 | $43.31 |
Enterprise Value | $287.47B | $11.32B |
Dividend Yield | 3.47% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $88.50, down 1.23% today, with a bullish technical signal from moving averages and neutral oscillators. Recent earnings beat expectations in Q1 and Q2 2026, driven by higher oil prices and operational gains. The company maintains strong cash flow, reduced debt, and a discounted valuation with a P/E of 9.79. Analysts show strong buy sentiment, with a consensus price target of $103.60, and recent news highlights strategic asset sales and investments in gas projects.
Outlook is positive with earnings momentum and shareholder returns via dividends and buybacks, but risks include oil price volatility and regulatory pressures. The stock offers value with upside potential, though investors should monitor commodity swings and geopolitical factors affecting energy markets.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →